HitGen's latest marketcap:
As of 08/13/2025, HitGen's market capitalization has reached $1.24 B. According to our data, HitGen is the 8735th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 1.24 B |
| Revenue (ttm) | 59.41 M |
| Net Income (ttm) | 9.16 M |
| Shares Out | 399.44 M |
| EPS (ttm) | 0.02 |
| Forward PE | 142.21 |
| Ex-Dividend Date | 06/18/2025 |
| Earnings Date | 08/28/2025 |
HitGen's yearly market capitalization.
| Date | Market Cap(¥) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 08/13/2025 | ¥8.9 B | $1.24 B | 86.2% | 8735 |
| 12/31/2024 | ¥4.92 B | $673.95 M | -17.81% | 11052 |
| 12/29/2023 | ¥5.99 B | $843.3 M | 10.86% | 9652 |
| 12/30/2022 | ¥5.4 B | $782.63 M | -42.61% | 9587 |
| 12/31/2021 | ¥9.41 B | $1.48 B | -22.01% | 7362 |
| 12/31/2020 | ¥12.07 B | $1.85 B | 5605 |
Company Profile
About HitGen Inc.
HitGen Inc. is a leading drug discovery research platform specializing in small molecules and nucleic acid drugs, operating in China and internationally. Founded in 2012 and headquartered in Chengdu, China, the company leverages cutting-edge technologies to advance therapeutic solutions.
Technology Platforms
- DNA-encoded library technology
- Fragment-based drug discovery and structure-based drug design
- Synthetic therapeutic oligonucleotide technology
- Targeted protein degradation technology
Product Pipeline
Small Molecule Drugs:
- HG146: Selective HDAC inhibitor for multiple myeloma and solid tumors
- HG030: Second-generation NTRK/ROS1 inhibitor for solid tumors
- HG381: Immune-oncology agonist for cancer
- HGT01 & HGT02: Tumor immunology therapies
- HGT03: Protein degrader
- HGT04: Transcriptomics for cancer
- HGT05: Kinase inhibitor for liver cancer
- HGP0508: Small molecule for anti-inflammatory therapeutics
- HGC245: Kinase inhibitor for glaucoma
Nucleic Acid Drugs:
- HGP2142: TGF-β1 specific siRNA drug for liver cancer
- HGN001: Nucleic acid drug for specific cancer mutations
- HGN002: For solid tumors
Services
HitGen offers comprehensive drug discovery services, including:
- Target validation
- Hit identification and hit-to-lead optimization
- Lead optimization
- Preclinical studies and IND support
- Clinical development
- Integrated drug discovery
Therapeutic Focus Areas
The company specializes in:
- Oncology and immuno-oncology
- Inflammatory and autoimmune diseases
- Ophthalmology
- Infectious, metabolic, and cardiovascular diseases
Frequently Asked Questions
-
What is HitGen's (SHA-688222) current market cap?As of 08/13/2025, HitGen (including the parent company, if applicable) has an estimated market capitalization of $1.24 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does HitGen (SHA-688222) rank globally by market cap?HitGen global market capitalization ranking is approximately 8735 as of 08/13/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.